OSR Health (OSRHW) Change in Accured Expenses (2022 - 2026)
OSR Health (OSRHW) posted Change in Accured Expenses of $44495.6 for Q1 2026, down 91.94% sequentially from $552338.0 in Q4 2025, and up 396.47% YoY from $8962.5 in Q1 2025.
OSR Health (OSRHW) Change in Accured Expenses (2022 - 2026) Analysis & Trends
OSR Health has reported Change in Accured Expenses for 5 years, with the latest figure at $44495.6 in Q1 2026.
- Quarterly Change in Accured Expenses rose 396.47% year-over-year to $44495.6 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $512178.2 (up 3123.99% YoY) and the FY2025 annual result came in at $476645.0, up 13952.03% from the prior year.
- Change in Accured Expenses declined to $44495.6 in Q1 2026 per OSRHW's latest filing, from $552338.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $581399.0 in Q4 2023 and troughed at -$119947.0 in Q2 2023.
- A 5-year average of $106469.0 and a median of $13300.0 in 2022 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses soared 4271.42% in 2023, then sank 189.82% in 2025.
- Over 5 years, Change in Accured Expenses stood at $13300.0 in 2022, then jumped by 4271.42% to $581399.0 in 2023, then tumbled by 103.45% to -$20055.0 in 2024, then surged by 2854.12% to $552338.0 in 2025, then plunged by 91.94% to $44495.6 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $44495.6, $552338.0, and -$30272.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.97 Bn | 131.12 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.15 Bn | 77.15 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 62.84 Bn | 57.65 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.74 Bn | 50.60 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.53 Bn | 36.43 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 27.32 Bn | 8.93 Bn | 668.28 Mn | - |
| 8 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | - |
| 9 | Insmed | 26.99 Bn | 25.83 Bn | 358.27 Mn | 68.82 Mn |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 | -2.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44,495.64 |
| Mar 31, 2026 | 44,495.64 |
| Dec 31, 2025 | 552,338.00 |
| Dec 31, 2025 | 552,338.00 |
| Sep 30, 2025 | -30,272.00 |
| Sep 30, 2025 | -30,272.00 |
| Jun 30, 2025 | -54,383.47 |
| Jun 30, 2025 | -54,383.47 |
| Mar 31, 2025 | 8,962.47 |
| Mar 31, 2025 | 8,962.47 |
| Dec 31, 2024 | -20,055.00 |
| Dec 31, 2024 | -20,055.00 |
| Sep 30, 2024 | -33,566.00 |
| Sep 30, 2024 | -33,566.00 |
| Jun 30, 2024 | 60,545.00 |
| Jun 30, 2024 | 60,545.00 |
| Mar 31, 2024 | -3,532.00 |
| Mar 31, 2024 | -3,532.00 |
| Dec 31, 2023 | 581,399.00 |
| Dec 31, 2023 | 581,399.00 |